T-Oncology AG is focusing on improving patients´ lifes and helping caregivers to have options in the treatment of cancer. Our company works from a proprietary development platform to select small domain antibody fragments to develop drug conjugates to aim at well-known targets (HER2+), but also new ones. (Please inquire for more details) Our initial mission is aiming at the unmet need to target brain metastasis from HER2+ lung, breast, bladder and colonrectal cancer. We will not give up, for you to have an option and hope!
